Chin Named Chief Financial Officer of Akido     Eric Chin is the new Chief Financial...

<!– Medical Innovation Exchange February 7, 2023 6:40 am Neural Chip Detects, Suppresses Neurological Symptoms

<!– Medical Innovation Exchange February 7, 2023 6:22 am Antibacterial Peptide Spray Safe for Use...

<!– Medical Innovation Exchange February 7, 2023 6:06 am Tiny Patch for Cardiac Ultrasound Imaging

Rocket, putting regulatory roadblocks in its rearview, receives show of confidence in gene therapy from...

Investor Syncona blames bear market's ravaging of British biotechs for ‘disappointing’ returns February 7, 2023...

Roche races to regulators after matching AstraZeneca’s rare disease blockbuster in phase 3 February 7,...

Acute Pulmonary Exacerbations Present Inherent Clinical Challenges, For Now     Pulmonary exacerbation is a serious...

Do we need new Alzheimer's scales, or a new perspective on what's meaningful to patients?...

Cell therapy biotech lays off 25% of staff citing difficult funding environment February 6, 2023...

BMS returns $475M IL-12 oncology asset to Dragonfly’s pond February 6, 2023 6:38 am https://www.fiercebiotech.com/biotech/bms-returns-475m-oncology-asset-back-dragonflys-pond

GSK's retrospective trial diversity study shows there's more work to do February 6, 2023 5:42...

J&J's latest data for nipocalimab in fetal disorder suggests Momenta acquisition may still pay off...

Boarding priority review track, Biogen and Sage get August decision date for depression drug approval...

Ex-Shire drug improves outcomes in autoimmune disease, setting Certa on path to phase 3 February...

<!– Medical Innovation Exchange February 3, 2023 12:06 pm Pop-Up Electrode for Improved Neural Interfaces

4D in unknown dimension as FDA slaps hold on Fabry gene therapy trial February 3,...

Bruised by high profile cancer setbacks, Sanofi CEO plots early-stage path ‘back to the magic’...

Drug discovery biotech Vyant preps to wind down operations, starting with layoffs February 3, 2023...

Chutes & Ladders—Ginkgo BioWorks CEO to lead federal biotech commission February 3, 2023 5:13 am...

Is MaaT back? After 18 months on hold, microbiome biotech sees end to impasse with...

Sanofi backs down from fight with AstraZeneca, argenx and more by stopping phase 3 trial...

Gilead puts 3 programs on chopping block, including 2 of 3 indications for IRAK4 inhibitor...

Days after halting leukemia drug, Magenta moves to close its doors February 2, 2023 12:44...

BMS knocks down a handful of early cancer candidates amid pipeline cleanout February 2, 2023...

Lilly execs shrug off Alzheimer's rejection while assuring investors safety was not an issue February...

Merck admits defeat in race with Valneva to get first chikungunya vaccine to market February...

Purple Biotech to paint with Immunorizon's tri-specific antibodies in small M&A deal February 2, 2023...

Inovio hopes Ebola vaccine booster data can provide a shot in the arm February 2,...

Lilly drops 2nd program against NASH target that caught Pfizer's eye February 2, 2023 4:17...

Karuna plunders Goldfinch's nest with hopes of repurposing kidney candidates for neuroscience February 2, 2023...

The AKT is over: Roche finally dumps phase 3 prostate cancer prospect February 1, 2023...

Mesoblast gives allogeneic cell therapy a 2nd try with FDA—but without a new trial February...

Innovation, investment in pain and addiction are not meeting the societal burden, report says February...

Cleeland Joins Francis Medical Board of Directors     Andrew Cleeland, CEO of Fogarty Innovations, has...

Novartis hasn’t given up on TIGIT, CEO insists, as Big Pharma ‘active’ in cancer M&A...

Embattled Evelo hangs on to CEO while letting go of 48 employees after eczema trial...

Two announcements occurred this week, both of note and connected only by the fact that...

2nd round of layoffs in 2 months for Instil, as cell therapy manufacturing shifts to...

GSK drops celiac program acquired in Sitari buyout—and delivers blow to bid to avert antibiotic...

Novartis cans branaplam after seeing Huntington’s safety signal, delays orphan drug over slow enrollment February...

The Turing Test is Dead     In May 2018, Google showcased a demo of Google...

Layoffs continue to batter biotech, with Big Pharmas piling on the pain January 31, 2023...

Pfizer CEO says R&D is the 'lifeblood that fuels us,' as spending revs up post-COVID...

Despite blockbuster Altos funding, longevity-focused investment drops by $1B: report January 31, 2023 6:40 am...

After snagging most expensive drug title, uniQure doles out $10M upfront for ALS prospect January...

Inovio orders 2nd round of layoffs in 6 months after vaccine flops January 31, 2023...

Pfizer punts pair of orphan drugs amid rare disease R&D rethink January 31, 2023 4:33...

Gilead nixes Matinas oral COVID-19 antiviral to focus on late-phase internal program January 31, 2023...

<!– Medical Innovation Exchange January 30, 2023 10:49 pm Microneedle Bandage for Hemostatic Control

<!– Medical Innovation Exchange January 30, 2023 10:43 pm Flexible Sensors Detect Heavy Metals in...

Quince lays off 47% of staff, stakes sale sign for asset days after separate pipeline...

FDA Issues Final Guidance on Surveying, Leveling, and Alignment Laser Products     On January 30,...

Moderna’s RSV shot nabs FDA breakthrough tag, joining Pfizer, GSK in race to approval January...

Structure finalizes $111M IPO while cancer-focused Intensity reveals Nasdaq ambitions January 30, 2023 5:57 am...

After 'half-baked' data drop, CureVac releases results on mRNA flu, COVID-19 vaccines in older adults...

<!– Medical Innovation Exchange January 30, 2023 12:31 am Ultrasound Tornado Rapidly Disrupts Blood Clots

<!– Medical Innovation Exchange January 30, 2023 12:24 am Nanopore Sensor to Study Protein Aggregation...

<!– Medical Innovation Exchange January 30, 2023 12:13 am Smart Walking Stick for Visually Impaired...

How Real-World Evidence Helps Medical Device Manufacturers Drive Value     Real-world evidence (RWE) captured during...

Biotech pipeline hosts 163 potential meds for mental illness, with depression dominating: PhRMA January 27,...

Neither ear nor there: Altamira stakes for-sale sign again after asset deal crumbles January 27,...

Goldfinch Bio falls from the sky after failing to find a path forward for kidney...

Quince's former leadership returns to scoop up unwanted Alzheimer's assets January 27, 2023 6:02 am...

Senti slams brakes on CAR-NK program to eke out remaining cash January 27, 2023 4:50...

Celularity warns 'substantial portion' of staff about possible layoffs after reviewing cell therapy strategy January...

UK biotech IPOs fell to lowest level for a decade in 2022, but VC funds...

Chutes & Ladders—Johnson & Johnson CMO Joanne Waldstreicher announces retirement January 26, 2023 11:33 am...

XyloCor gene therapy hits goals, paving way for phase 3 in cardiovascular space with no...

2 deals in 2 weeks: GenKOre signs pacts worth up to $650M biobucks for gene-editing...

As Sesen investors allege a 'bribe' was offered to support planned Carisma merger, company says...

Sanofi dives deeper into phase 3 data for Hemlibra rival as FDA decision approaches January...

Early data from AC Immune Alzheimer's vaccine suggests a response, setting up next phase of...

Each year Eye on FDA provides a look-back to see what the agency was talking...

Miss for Aridis as antibody flunks undersized phase 3 pneumonia trial January 26, 2023 4:27...

Ocuphire still focused on FDA approval despite diabetic eye drug missing phase 2 endpoint January...

After dose de-escalation, death drives Magenta to pause antibody-drug conjugate leukemia trial January 26, 2023...

Inhibikase, FDA find common ground to lift hold on Parkinson's drug January 25, 2023 7:12...

Creating a new dimension: Biotech VC merging tech and life sciences unveils with $350M January...

Cidara wins ‘difficult’ AdComm vote, securing near-unanimous support despite antifungal data doubts January 25, 2023...

Connected Care: Overcoming Roadblocks and Identifying Opportunities     What’s next—and what’s holding us back—on the...

KSQ scores 'double-digit million' payment from Japan's Ono for preclinical cancer programs January 25, 2023...

Bristol Myers CMO still skeptical about cancer vaccines as BioNTech, Moderna march ahead with I-O...

EMA validates Vertex's CRISPR application, clearing barrier on road to landmark approval January 25, 2023...

Tackling Go-To-Market Challenges     The medical device industry is amid an era of unprecedented regulatory...

Matt Gline wants you to stop thinking of Roivant as a discard company. In 2023,...

Behind the deal: AstraZeneca’s eagerness for CinCor acquisition revealed in larger initial offer January 24,...

Cassava claims win in open-label Alzheimer's study, but shares decline 15% January 24, 2023 7:04...

J&J trims the edges of its pipeline with the company mum on timing of looming...

Frosty funding forecast forces Finch to stop phase 3 trial, lay off 95% of staff...

Law firms target Spectrum over lung cancer trial statements January 24, 2023 3:38 am https://www.fiercebiotech.com/biotech/law-firms-target-spectrum-over-disclosure-lung-cancer-data

The rise of venture debt and when biotechs should—and shouldn't—use it January 23, 2023 1:08...

Combo results may offer route back to approval for Agenus' unlucky cervical cancer drug January...

Merck KGaA shrinks U.S. research team as layoffs continue to batter industry January 23, 2023...

Morphic loses another Big Pharma partner as J&J follows AbbVie out of the door January...

Chasing Boehringer, Pliant sends stock soaring with midphase fibrosis data January 23, 2023 2:08 am...

Instilling Trust in AI     Artificial intelligence (AI) has become one of the most exciting...

FDA Seeks Input on Advancing Use of Real-World Data and Evidence     The FDA is...

Biotech may soon be defined by the 'haves and have-nots' as investors look for less...

<!– Medical Innovation Exchange January 20, 2023 8:06 am Balance Boards to Stay Active in...

<!– Medical Innovation Exchange January 20, 2023 7:54 am Biobots Use Optogenetic Muscle Actuators for...

Eyeing untapped niche, EpicentRx makes case for cancer toxicity prevention drug January 20, 2023 5:13...

Disc spins faster by paying Mabwell $10M for clinic-ready blood disorder candidate January 20, 2023...

Astellas, after years of gene therapy woes, gets rare boost with FDA lifting of Pompe...

Cyteir lays off 70% of workforce after further narrowing cancer drug goals January 20, 2023...

Eli Lilly shut out of Alzheimer’s fast lane with FDA rejection for donanemab January 19,...

Chutes & Ladders—David Kessler resigns from the Biden admin, marking the unofficial end of Operation...

<!– Medical Innovation Exchange January 19, 2023 11:09 am Artificial Neuron Uses Ions Like the...

Concert joins Sun Pharma’s symphony for $576M with aim of bringing alopecia treatment to market...

Jiving with Jazz after $325M opt-in, Zymeworks links HER2 bispecific to 84% survival after 18...

Editas finds buyer for iNK programs 10 days after clearing out pipeline January 19, 2023...

ReNeuron lays off 40% of staff after funding failure, buying time to execute exosome pivot...

Mineralys polishes $100M IPO plans ahead of phase 3 in hypertension January 19, 2023 2:17...

FDA To Host Webinar on Electromagnetic Compatibility of In Vitro Diagnostic Devices     The FDA...

Gilead fosters growth with plans for new research center in California hometown January 18, 2023...

SPAC to it: Alzheimer’s-focused Aprinoia inks deal with Wilbur Ross' blank check company January 18,...

J&J packs up HIV vaccine after failing phase 3 trial January 18, 2023 6:24 am...

Irlab's shares plummet 60% after Ipsen-partnered Parkinson's drug flunks phase 2 trial January 18, 2023...

<!– Medical Innovation Exchange January 18, 2023 5:54 am Hydrogel Scaffold Makes a Living Electrode

Horizon, on victory lap before Amgen buyout, racks up 2nd win in Sjögren's to claim...

Phase 2 attrition jumps amid widespread scale-back in overall clinical trial activity: study January 18,...

Intricon Launches Biosensors Center of Excellence     Intricon, a developer and manufacturer of medical devices...

How 2 biotechs survived 2022’s rocky market—and why their CEOs see success on the horizon...

Sustainability: Lessons from the Frontlines of Health Care     Healthcare leaders today face the complicated...

Playing catch-up to Big Pharma, Moderna posts come-from-behind RSV data January 17, 2023 11:09 am...

A trio of biotechs consolidate as M&A fails to materialize at JPM January 17, 2023...

NewAmsterdam's Amgen castoff cuts LDL cholesterol in phase 2, opening new front in race to...

Elicio uses struggling Angion as route to Nasdaq ahead of cancer vaccine's phase 2 move...

First hiccup for Basilea's anti-infective strategy as biotech hands back antifungal 9 months after licensing...

Abionyx hails success of bid to resurrect failed cholesterol drug—without dishing data to back up...

Through its Human Drugs Advisory Committee process FDA has a vast array of outside experts...

TCR² removed 20% of staff over summer, paving way for latest layoffs January 13, 2023...

Chutes & Ladders—Novavax CEO Erck bids adieu after 12 years, overseeing COVID vax development January...

Using real RWD to better understand and engage neuro patients January 12, 2023 9:42 am...

Sanofi pumps $750M into VC unit to push deeper into biotech investing January 12, 2023...

JPM23: After hiatus, Teva looks to amp up research collaborations, CEO says January 12, 2023...

GSK grabs 150K square feet of prime Boston lab space as part of RNA, viral...

Oramed’s oral insulin flunks phase 3 diabetes test, sending stock down 70% January 12, 2023...

JPM23: After rock climbing in biotech, Novartis’ CMO is back to support hopeful hike to...

JPM23: Nektar pins comeback hopes on Lilly collab and cancer combinator following bempeg blowup January...

Enhancing Clinical Trials with More Diverse Recruitment January 11, 2023 11:21 am https://www.fiercebiotech.com/sponsored/deconstructing-what-causes-clinical-trials-fall-short

JPM23: Ionis CEO admits PCSK9 ship captained by Big Pharmas may have sailed January 11,...

JPM23: Annexon looks for 'two ways to win' in upcoming Huntington's trial January 11, 2023...

4D's Fabry gene therapy flounders amid adverse events, further weakening Sangamo's competition January 11, 2023...

BioXcel, keeping cards close to its chest, teases phase 2 Keytruda combination trial data drop...

European Commission Proposes Extended Timeline for EU MDR/IVDR Compliance       On January 6, the...

JPM23: Editas touts skinnier pipeline after major shake-up to ride out 'unfriendly' markets January 11,...

JPM23, Day 3: Takeda relishing in-person meetups January 11, 2023 12:56 am https://www.fiercebiotech.com/biotech/jpm23-day-3-takeda-relishing-person-meet-ups

Best Practices and Pitfalls When Going from Concept to Commercialization     MedTech Internet of things...

JPM23: BioNTech not giving up on fighting symptomatic COVID as oncology ambitions spread January 10,...

JPM23: Sage CEO says postpartum depression is no niche, as zuranolone aims to fill gaps...

JPM23: Karuna CEO says biotech can launch drugs too, as deal rumors circulate January 10,...

King Joins KMM Group as Healthcare Industry Advisor     J. Mark King, a long-time healthcare...

JPM23: Roivant CEO says 2023 shaping up to be 'single most exciting year' for new...

Jasper pulls out of pivotal blood cancer trial at the last minute to prioritize other...

Alto’s hopes for brain biomarker strategy rise on phase 2 antidepressant data January 10, 2023...

AbbVie, following in footsteps of Lilly and Takeda, pays Anima $42M to go after undruggable...

JPM23, Day 2: VCs still have cash to fund biotech, says investor January 10, 2023...

Cash-strapped Calithera closes down in shadow of enrollment delays to cancer trials January 10, 2023...

New Cybersecurity Standards for Medical Applications     An increasing number of pacemakers, insulin pumps and...

JPM23: Beam hopes to sidestep sickle cell peers with next-gen gene editing January 9, 2023...

JPM23: Lilly has a full plate, as CMO jokes, 'we need to leave J.P. Morgan...

JPM23: Mirati's post-Krazati pipeline restock to focus on 'highest opportunity for capital' January 9, 2023...

Annexon, Liminal shrink pipelines to prioritize potential homerun candidates January 9, 2023 6:56 am https://www.fiercebiotech.com/biotech/annexon-liminal-shrink-pipelines-prioritize-potential-homerun-candidates

Good day for Day One as pediatric brain tumor drug proves worth in phase 2...

Takeda, Arrowhead hit one target for rare disease drug, but placebo overperformance sends biotech's shares...

Boehringer offers 3T Biosciences $268M to plug its data into biotech's TCR cancer platform January...

Pharvaris to embark on 6-month tox test in hopes of reversing US clinical hold for...

Novavax CEO Stanley Erck retires after overseeing COVID shot launch January 9, 2023 5:36 am...

Astellas continues intergalactic licensing quest, signing onto 2 new pacts January 9, 2023 5:29 am...

Editas rewrites its own code after tough 2022, sending staff packing and editing down programs...

Neurocrine blows fresh wind in Voyager's sails with $175M upfront for CNS capsid collab January...

Lilly rides TRex into regulatory T-cell space, paying $55M upfront for 3 immune-mediated disease drugs...

Stalicla pledges $270M to take forward Novartis’ failed former fragile X candidate January 9, 2023...

Capitalizing on share price crash, AstraZeneca inks $1.8B CinCor takeover for blood pressure drug January...

JPM23, Day 1: AstraZeneca scoops CinCor for cardiorenal drug; Genentech seals small molecule pact January...

Roche offers up to $554M in biobucks to in-need Kronos for small molecule discovery pact...

Flagship Pioneering CEO urges shareholders to stay the course on 'choppy' biotech markets: 'See you...

Fierce Biotech Layoff Tracker 2023: Editas edits down workforce, plus more January 6, 2023 11:49...

Karuna parts ways with executive as it gears up for schizophrenia drug's high-profile launch January...

<!– Medical Innovation Exchange January 6, 2023 7:45 am Bioprinted Eye Tissue to Study Retinal...

BioNTech signs UK government pact to deliver cancer therapies to 100k patients by 2023 January...

AbbVie inks $1.3B biobucks deal with Immonome in hopes of developing antibody therapeutics for solid...

CureVac's 'half-baked' COVID-flu data release questioned by analysts, but shares still rally 17% January 6,...

Century, Elevation are latest to follow layoff, pipeline cull route as Nabriva winds down January...

Moderna caps off busy week with $1.2B CytomX collab to better target mRNA therapies January...

Pfizer pivots from early-stage rare disease R&D, shifting to external innovation and putting assets up...

Fate hits reset as J&J cell therapy deal collapses, slashing pipeline and head count to...

Graphite's hopes for sickle cell 'cure' blunted after first patient dosed experiences serious event January...

Chutes & Ladders—2 more C-suite members leave Galapagos island January 5, 2023 3:22 pm https://www.fiercebiotech.com/biotech/chutes-ladders-galapagos-sees-two-more-c-suite-members-leave-island

<!– Medical Innovation Exchange January 5, 2023 9:52 am Point-Of-Care Biosensor to Detect Oral Cancer

<!– Medical Innovation Exchange January 5, 2023 9:22 am Optogenetics Tech for Long-Term Changes in...

Roche further taps drug discovery spinout's Nimble tech in $1.1B biobucks deal January 5, 2023...

Renibus’ cardiac surgery drug aces phase 2 trial as biotech adds extra CEO January 5,...

Amgen piles $2B more into pharma's ADC rush in Synaffix pact January 5, 2023 5:48...

Takeda troops rare disease drug to regulators after glimpse at phase 3 data January 5,...

Burned by FDA rejection, Y-mAbs drops 3rd of staff, cancer vaccine ambitions January 5, 2023...

GSK pays WuXi $40M, bets $1.5B in biobucks for preclinical anti-cancer bispecific antibodies January 5,...

Biopharmas left Black and Latinx patients behind in oncology clinical trials, nonprofit says January 4,...

Eisai rebuts NEJM report that Alzheimer's med contributed to patient's stroke death January 4, 2023...